PAR-22-032

Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)

Federal Opportunity Search » Grant Opportunity

This federal contracting opportunity for National Institutes of Health, Health and Human Services, provides products and/or services. The original notice was posted on Nov 17, 2021 and last updated Nov 17, 2021 with a response date of Jan 7, 2025.

Most recently (Nov 17, 2021), the solicitation notice, solicitation number was changed, response date was moved to Jan 07, 2025, buying agency was changed, industry classification was changed, contracting officer contact information was updated, and description was updated.

The civilian buyer (National Institutes of Health) from Health and Human Services spent $8B in federal contracting dollars in fiscal year 2023 with a stable budget forecast heading into FY24. National Institutes of Health shows unrestricted competition preference with 10.68% in set aside dollars (versus full and open competiton).

Read the full report

Solicitation Number: PAR-22-032

Contracting Agency/Office: Department of Health and Human Services/National Institutes of Health

Posted Date: 11/17/2021 12:00 AM

Response Date: 01/07/2025 12:00 AM

Set-Aside: N/A

Primary Contact: phone and email address of primary contact

Document Type: Grants Notice

Opportunity Number: PAR-22-032

Opportunity Title: Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)

Opportunity Category: Discretionary

Funding Instrument Type: Grant

Category of Funding Activity: Education
Health

Expected Number of Awards

CFDA Number(s): 93.242 -- Mental Health Research Grants
93.273 -- Alcohol Research Programs
93.279 -- Drug Abuse and Addiction Research Programs
93.866 -- Aging Research
--

Cost Sharing or Matching Requirement: No

Read the full report

Win More Federal Business

Imagine a world where every report, every insight is tailored specifically to you. Our entire platform is configured around your past performance so that everything is relevant.